Lp(a) is not associated with diabetes but affects fibrinolysis and clot structure ex vivo

Marianne Månsson, Inge Kalies, Göran Bergström, Caroline Schmidt, Anne Legnehed, Lillemor Mattsson Hultén, Lena Amrot-Fors, David Gustafsson, Wolfgang Knecht

Research output: Contribution to journalArticlepeer-review

Abstract

Lipoprotein (a) [Lp(a)] is a low density lipoprotein (LDL) with one apolipoprotein (a) molecule bound to the apolipoprotein B-100 of LDL. Lp(a) is an independent risk factor for cardiovascular disease (CVD). However, the relationship of Lp(a) to diabetes and metabolic syndrome, both known for increased CVD risk, is controversial. In a population based study on type two diabetes mellitus (T2DM) development in women, Lp(a) plasma levels showed the well known skewed distribution without any relation to diabetes or impaired glucose tolerance. A modified clot lysis assay on a subset of 274 subjects showed significantly increased clot lysis times in T2DM subjects, despite inhibition of PAI-1 and TAFI. Lp(a) plasma levels significantly increased the maximal peak height of the clot lysis curve, indicating a change in clot structure. In this study Lp(a) is not related to the development of T2DM but may affect clot structure ex vivo without a prolongation of the clot lysis time.

Original languageEnglish
Article number5318
Number of pages7
JournalScientific Reports
Volume4
DOIs
Publication statusPublished - 2014 Jun 17
Externally publishedYes

Free keywords

  • Aged
  • Analysis of Variance
  • Blood Coagulation
  • Blood Coagulation Tests
  • Carboxypeptidase B2/blood
  • Diabetes Mellitus, Type 2/blood
  • Female
  • Fibrinolysis
  • Humans
  • Lipoprotein(a)/blood
  • Middle Aged
  • Plasminogen Activator Inhibitor 1/metabolism

Fingerprint

Dive into the research topics of 'Lp(a) is not associated with diabetes but affects fibrinolysis and clot structure ex vivo'. Together they form a unique fingerprint.

Cite this